{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:26:49Z","timestamp":1790630809066,"version":"4.1.0"},"reference-count":55,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Croatian Cooperative Group for Hematologic Diseases (KroHem)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1273, BNT162b2, or ChAdOx1 nCoV-19 vaccine in 118 patients with different malignant or non-malignant hematologic diseases from three Croatian treatment centers. An electrochemiluminescent assay was used to measure total anti-SARS-CoV-2 S-RBD antibody titers. After one vaccine dose, 20\/66 (33%) achieved seropositivity with a median antibody titer of 6.1 U\/mL. The response rate (58\/90, 64.4%) and median antibody titer (&gt;250 U\/mL) were higher after two doses. Seropositivity varied with diagnosis (overall p &lt; 0.001), with the lowest rates in lymphoma (34.6%) and chronic lymphocytic leukemia (52.5%). The overall response rate in chronic myeloproliferative neoplasms (CMPN) was 81.3% but reached 100% in chronic myeloid leukemia and other non-myelofibrosis CMPN. At univariable analysis, age &gt; 67 years, non-Hodgkin\u2019s lymphoma, active treatment, and anti-CD20 monoclonal antibody therapy increased the likelihood of no vaccine response, while hematopoietic stem cell recipients were more likely to respond. Age and anti-CD20 monoclonal antibody therapy remained associated with no response in a multivariable model. Patients with the hematologic disease have attenuated responses to SARS-CoV-2 vaccines, and significant variations in different disease subgroups warrant an individualized approach.<\/jats:p>","DOI":"10.3390\/biomedicines10112892","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T04:14:01Z","timestamp":1668399241000},"page":"2892","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-4283","authenticated-orcid":false,"given":"Zrinka","family":"Serti\u0107","sequence":"first","affiliation":[{"name":"Institute for Emergency Medicine Krapina-Zagorje County, 49 000 Krapina, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-2040","authenticated-orcid":false,"given":"Marko","family":"Lucijani\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia"},{"name":"Clinical Hospital Dubrava, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ba\u0161i\u0107-Kinda","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranka","family":"Serventi Seiwerth","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlatka","family":"Peri\u0161a","sequence":"additional","affiliation":[{"name":"University Hospital Centre Osijek, 31 000 Osijek, Croatia"},{"name":"Faculty of Medicine Osijek, University J.J. Strossmayer Osijek, 31 000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravka","family":"Serti\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017eena","family":"Coha","sequence":"additional","affiliation":[{"name":"General Hospital \u201cDr. Josip Ben\u010devi\u0107\u201d Slavonski Brod, 35 000 Slavonski Brod, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dra\u017een","family":"Pulani\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia"},{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peri\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia"},{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Desnica","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirta","family":"Mikuli\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijo","family":"Vodanovi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Radman-Livaja","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"\u0160egulja","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunja","family":"Rogi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Valkovi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Center Rijeka, 51 000 Rijeka, Croatia"},{"name":"Medical School, University of Rijeka, 51 000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Aurer","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia"},{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5842-0911","authenticated-orcid":false,"given":"Nadira","family":"Durakovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia"},{"name":"University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study","volume":"13","author":"Cedillo","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijid.2007.06.004","article-title":"Efficacy of accelerated hepatitis B vaccination program in patients being actively treated for hematologic malignancies","volume":"12","author":"Pullukcu","year":"2008","journal-title":"Int. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2016044","DOI":"10.4084\/mjhid.2016.044","article-title":"Influenza and pneumococcal vaccination in hematological malignancies: A systematic review of efficacy, effectiveness and safety","volume":"8","year":"2016","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1473-3099(19)30310-X","article-title":"Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: A two-arm, randomised, double-blind, phase 3 trial","volume":"19","author":"Mullane","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccell.2021.01.001","article-title":"Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients","volume":"39","author":"Alaguthurai","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Gutwein","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofab353","DOI":"10.1093\/ofid\/ofab353","article-title":"Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era","volume":"8","author":"Agha","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-022-04866-z","article-title":"Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases","volume":"101","author":"Rotterdam","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_16","unstructured":"(2022, October 29). 2022. Elecsys\u00ae Anti-SARS-CoV-2 S. Material Number 09289267190, Method Sheet 2022-07, V3.0. Material Number 09289275190, Method Sheet 2022-06, V4.0. Available online: https:\/\/diagnostics.roche.com\/content\/dam\/diagnostics\/Blueprint\/en\/pdf\/cps\/factsheet-elecsys-anti-sars-cov-2-s-mc--05522.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cca.2021.08.024","article-title":"Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects","volume":"522","author":"Ferrari","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A Modified Poisson Regression Approach to Prospective Studies with Binary Data","volume":"159","author":"Zou","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjh.17890","article-title":"COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report","volume":"196","author":"Breccia","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/s41375-021-01300-7","article-title":"Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms","volume":"35","author":"Harrington","year":"2021","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41375-021-01143-2","article-title":"Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm","volume":"35","author":"Salisbury","year":"2021","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: A national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"E408","DOI":"10.1002\/ajh.26305","article-title":"Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib","volume":"96","author":"Guglielmelli","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41408-021-00579-0","article-title":"Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience","volume":"11","author":"Cattaneo","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00277-021-04613-w","article-title":"Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis","volume":"101","author":"Caocci","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2665-9913(22)00044-3","article-title":"Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Han","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41375-020-0832-y","article-title":"Frequently asked questions regarding SARS-CoV-2 in cancer patients\u2014Recommendations for clinicians caring for patients with malignant diseases","volume":"34","author":"Vehreschild","year":"2020","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Terpos, E., Gavriatopoulou, M., Fotiou, D., Giatra, C., Asimakopoulos, I., Dimou, M., Sklirou, A.D., Ntanasis-Stathopoulos, I., Darmani, I., and Briasoulis, A. (2021). Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers, 13.","DOI":"10.3390\/cancers13174480"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell\u2013directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: Preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Gleason","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(21)01594-4","article-title":"Antibody response after second BNT162b2 dose in allogeneic HSCT recipients","volume":"398","author":"Redjoul","year":"2021","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood.2021014232","article-title":"Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients","volume":"139","author":"Maillard","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.26385","article-title":"SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group","volume":"97","author":"Martino","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Andrews","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"940956","DOI":"10.3389\/fpubh.2022.940956","article-title":"The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis","volume":"10","author":"Zou","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e220446","DOI":"10.1001\/jamaoncol.2022.0446","article-title":"Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients","volume":"8","author":"Obeid","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15585\/mmwr.mm7104a2","article-title":"Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults\u2014United States, August\u2013December 2021","volume":"71","author":"Tenforde","year":"2022","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1016\/S2352-3026(21)00274-X","article-title":"Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT","volume":"8","author":"Redjoul","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2021014085","article-title":"Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination","volume":"139","author":"Herishanu","year":"2022","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41467-022-28578-0","article-title":"Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies","volume":"13","author":"Re","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1136\/annrheumdis-2021-220756","article-title":"Correspondence on \u2018SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response\u2019","volume":"80","author":"Westhoff","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjh.17877","article-title":"T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies","volume":"196","author":"Marasco","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/11\/2892\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:14:21Z","timestamp":1760145261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/11\/2892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["biomedicines10112892"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10112892","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}